Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-010 in refractory systemic lupus erythematosus
NCT06752876Phase 1Withdrawn
- Sponsor
- Caribou Biosciences
- Start
- Dec 2027
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label trial of vispacabtagene regedleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 cohorts), sponsored by Caribou Biosciences. Primary endpoints: Incidence of critical safety events at 28 days and Incidence of treatment emergent adverse events at 2 years. Planned start Dec 2027; status: withdrawn.
02
Drugs
vispacabtagene regedleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06752876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752876.